GSK-MEK111054



An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor GSK1120212 in Subjects with Solid Tumors or Lymphoma
trametinib
MEK111054
NCT00687622
Solid Tumours
Phase 1
 
September 2013